In vivo antitumor activity of liposome‑plasmid DNA encoding mutant survivin‑T34A in cervical cancer

Qiu,Fang; Zhao,Xia

doi:10.3892/mmr.2018.9007

In vivo antitumor activity of liposome‑plasmid DNA encoding mutant survivin‑T34A in cervical cancer

Authors:
- Fang Qiu
- Xia Zhao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: May 11, 2018 https://doi.org/10.3892/mmr.2018.9007
Pages: 841-847
Copyright: © Qiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the influence of liposome‑plasmid encoding mutant survivin‑T34A (PST34A) on tumor growth in cervical cancer in vivo. Liposome‑plasmid DNA encoding mutant survivin‑T34A was constructed and administered via an intraperitoneal injection in mice inoculated with cervical cancer cells. Following the establishment of the tumor model, the animals were randomly divided into four groups: i) The normal saline group (NS; 100 µl sterile saline once/3 days for 15 days); ii) the 1,2‑dioleoyl‑3‑trimethylammonium‑propane (DOTAP) control (100 µg DOTAP once/3 days for 15 days); iii) the plasmid PST34A (10 µg PST34A once/3 days for 15 days); and iv) the PST34A+DOTAP (10 µg PST34A+100 µg DOTAP once/3 days for 15 days). All treatments were administered via intraperitoneal injections. Tumor growth was evaluated following injection with liposome‑plasmid DNA encoding mutant survivin‑T34A. Apoptosis of cells in ascitic fluid was detected by flow cytometry. The expression of Ki67 and CD34 was detected by immunohistochemical staining. Administration of liposome‑plasmid complexes encoding mutant survivin‑T34A inhibited tumor growth, reduced the number of tumor nodules and the volume of ascitic fluid, and decreased abdomen circumference and tumor weight. The number of Ki67‑positive cells was markedly reduced in the DOTAP+PST34A group compared with the remaining groups. Flow cytometry demonstrated that the number of cells in the sub‑G1 phase (apoptosis) increased in the DOTAP+PST34A group compared with all other groups. In addition, tumors in the DOTAP+PST34A group exhibited lower microvessel density compared with all other groups. In the present study, liposome‑plasmid DNA encoding mutant survivin‑T34A could inhibit tumor growth of cervical cancer. This inhibition may be associated with an increase in the apoptosis rate of tumor cells and a reduction in angiogenesis.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kabekkodu SP, Chakrabarty S, Ghosh S, Brand A and Satyamoorthy K: Epigenomics, pharmacoepigenomics and personalized medicine in cervical cancer. Public Health Genomics. 20:100–115. 2017. View Article : Google Scholar : PubMed/NCBI
3	Menderes G, Black J, Schwab CL and Santin AD: Immunotherapy and targeted therapy for cervical cancer: An update. Expert Rev Anticancer Ther. 16:83–98. 2016. View Article : Google Scholar : PubMed/NCBI
4	Kamer S, Ren Q and Dicker AP: Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet. 279:41–46. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yang Y, He L, Liu Y, Xia S, Fang A, Xie Y, Gan L, He Z, Tan X, Jiang C, et al: Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FR α. Sci Rep. 6:324272016. View Article : Google Scholar : PubMed/NCBI
6	Salvesen GS and Duckett CS: IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol. 3:401–410. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 6:127–134. 2000.PubMed/NCBI
8	Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
9	O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 156:393–398. 2000. View Article : Google Scholar : PubMed/NCBI
10	Moriai R, Asanuma K, Kobayashi D, Yajima T, Yagihashi A, Yamada M and Watanabe N: Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 21:595–600. 2001.PubMed/NCBI
11	Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kanwar JR, Shen WP, Kanwar RK, Berg RW and Krissansen GW: Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 93:1541–1552. 2001. View Article : Google Scholar : PubMed/NCBI
14	Jiang G, Li J, Zeng Z and Xian L: Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther. 5:435–440. 2006. View Article : Google Scholar : PubMed/NCBI
15	Pisarev V, Yu B, Salup R, Sherman S, Altieri DC and Gabrilovich DI: Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 9:6523–6533. 2003.PubMed/NCBI
16	Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL: Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells in vitro and in vivo. Oncol Lett. 11:159–167. 2016. View Article : Google Scholar : PubMed/NCBI
17	Fan Y and Chen J: Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis. Bioengineered. 8:511–523. 2017. View Article : Google Scholar : PubMed/NCBI
18	Pan L, Peng XC, Leng F, Yuan QZ, Shan Y, Yu DD, Li ZY, Chen X, Xiao WJ, Wen Y, et al: Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol. 137:19–28. 2011. View Article : Google Scholar : PubMed/NCBI
19	Song H, Xin XY, Xiao F, Wang DT, Han X and Guo HL: Influence of survivin gene repression by RNA interference on the radiosensitivity and chemosensitivity to cisplatin of cervical cancer cell HeLa. Zhonghua Fu Chan Ke Za Zhi. 41:554–558. 2006.(In Chinese). PubMed/NCBI
20	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
21	Mesri M, Wall NR, Li J, Kim RW and Altieri DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 108:981–990. 2001. View Article : Google Scholar : PubMed/NCBI
22	O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar : PubMed/NCBI
23	Wall NR, O'Connor DS, Plescia J, Pommier Y and Altieri DC: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63:230–235. 2003.PubMed/NCBI
24	Yu DD, Wang CT, Shi HS, Li ZY, Pan L, Yuan QZ, Leng F, Wen Y, Chen X and Wei YQ: Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res. 29:462010. View Article : Google Scholar : PubMed/NCBI
25	Yuan QZ, Wang CT, Mao YQ, Zhang P, Shi HS, Li ZY, Pan L, Yu DD, Leng F, Chen X, et al: Enhanced tumor radiosensitivity by a survivin dominant-negative mutant. Oncology Reports. 23:97–103. 2010.PubMed/NCBI
26	Zhou S, Li L, Jian X, Ou X, Jiang H, Yao Z, Xu C and Peng J: The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis. Oncol Rep. 20:1085–1091. 2008.PubMed/NCBI
27	Grossman D, Kim PJ, Schechner JS and Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA. 98:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
28	Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC and Reisfeld RA: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 65:553–561. 2005.PubMed/NCBI
29	Peng XC, Yang L, Yang LP, Mao YQ, Yang HS, Liu JY, Zhang DM, Chen LJ and Wei YQ: Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34->Ala mutant. J Exp Clin Cancer Res. 27:462008. View Article : Google Scholar : PubMed/NCBI
30	Hirko A, Tang F and Hughes JA: Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem. 10:1185–1193. 2003. View Article : Google Scholar : PubMed/NCBI